Cargando…

CYP2C192 and CYP2C1917 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset

The role of cytochrome P450 drug metabolizing enzymes in the efficacy of tamoxifen treatment of breast cancer is subject to substantial interest and controversy. CYP2D6 have been intensively studied, but the role of CYP2C19 is less elucidated, and we studied the association of CYPC19 genotype and re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Damkier, Per, Kjærsgaard, Anders, Barker, Kimberly A., Cronin-Fenton, Deidre, Crawford, Anatasha, Hellberg, Ylva, Janssen, Emilius A. M., Langefeld, Carl, Ahern, Thomas P., Lash, Timothy L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552748/ https://www.ncbi.nlm.nih.gov/pubmed/28798474 http://dx.doi.org/10.1038/s41598-017-08091-x

Ejemplares similares

Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients
por: Klebaner, Daniella, et al.
Publicado: (2017)

CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic
por: Dahabreh, Issa, et al.
Publicado: (2010)

CYP2D6 genotype and tamoxifen response
por: Rae, James M, et al.
Publicado: (2005)

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
por: Sanchez-Spitman, A. B., et al.
Publicado: (2021)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms
por: Reis, Sara S., et al.
Publicado: (2019)

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
por: Ferraldeschi, Roberta, et al.
Publicado: (2010)

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
por: Lee, Clara Inkyung, et al.
Publicado: (2020)

The ethics of CYP2D6 testing for patients considering tamoxifen
por: Hartman, Anne-Renee, et al.
Publicado: (2007)

Pharmacogenomics of CYP2C9: Functional and Clinical Considerations(†)
por: Daly, Ann K., et al.
Publicado: (2017)

Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen
por: Chamnanphon, Montri, et al.
Publicado: (2013)

Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen
por: Wigle, Theodore J., et al.
Publicado: (2017)

Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
por: Charoenchokthavee, Wanaporn, et al.
Publicado: (2016)

Impact of CYP2C9‐Interacting Drugs on Warfarin Pharmacogenomics
por: Agrawal, Saaket, et al.
Publicado: (2020)

Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
por: Charoenchokthavee, Wanaporn, et al.
Publicado: (2017)

CYP2D6 variants and the prediction of tamoxifen response in randomized patients: author response
por: Wegman, Pia P, et al.
Publicado: (2005)

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
por: Province, M A, et al.
Publicado: (2014)

CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
por: Brooks, Jennifer D., et al.
Publicado: (2018)

CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer
por: He, Wei, et al.
Publicado: (2020)

CYP2D6 and CYP2C19 Variant Coverage of Commercial Antidepressant Pharmacogenomic Testing Panels Available in Victoria, Australia
por: Forbes, Malcolm, et al.
Publicado: (2023)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
por: Kudzi, William, et al.
Publicado: (2009)

Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance
por: Dickschen, Kristin, et al.
Publicado: (2012)

Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment
por: Li, Jingmei, et al.
Publicado: (2013)

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
por: Sirachainan, Ekaphop, et al.
Publicado: (2012)

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
por: Brown, Sherry-Ann, et al.
Publicado: (2018)

Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example
por: Kisor, David F, et al.
Publicado: (2021)

The Effects of H(2)S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
por: Wang, Xianqin, et al.
Publicado: (2013)

Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment
por: Park, Hyung Seok, et al.
Publicado: (2011)

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy
por: Thompson, AM, et al.
Publicado: (2010)

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer
por: Lammers, L A, et al.
Publicado: (2010)

CYP2D6 Genotype and Tamoxifen Response for Breast Cancer: A Systematic Review and Meta-Analysis
por: Lum, Danny W. K., et al.
Publicado: (2013)

Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug–Drug Interaction with Antidepressants
por: MacLeod, A. Kenneth, et al.
Publicado: (2017)

Influence of CYP2D6 Polymorphisms on Serum Levels of Tamoxifen Metabolites in Spanish Women with Breast Cancer
por: Zafra-Ceres, Mercedes, et al.
Publicado: (2013)

National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China
por: Lin, Guigao, et al.
Publicado: (2016)

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
por: Schroth, Werner, et al.
Publicado: (2017)

CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients
por: Ahmed, Jemal Hussien, et al.
Publicado: (2019)

Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram
por: Lash, T L, et al.
Publicado: (2008)

Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites
por: Khalaj, Zahra, et al.
Publicado: (2019)

Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients
por: Fernández-Santander, Ana, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4au26llolelfv6a7r7lr1rb9qf